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Abstract
Introduction: Detection of human cytomegalovirus (CMV, HHV-5) DNA in clinical specimens is considered a cornerstone
in the diagnosis of HHV-5 disease. The present study compared two quantitative methods used for diagnosing cyto-
megalovirus infection in a 21-year-old woman with chronic myeloid leukemia after an unrelated umbilical cord blood trans-
plantation. 
Materials and Methods: Blood samples were tested for the presence of HHV-5 DNA using the LightCycler PCR, the quanti-
tative Eclipse® CMV DNA Detection Kit, and a qualitative in-house PCR assay using primers that amplify part of the HHV-5
MIE gene.
Results: Results from samples containing a low cytomegalovirus load were more accurate with the LightCycler test than those
obtained with the Eclipse® test, which underestimated the viral load of samples containing low DNA copy numbers.
Conclusions: These findings underline the value of novel PCR methods used in current therapeutic procedures and in mon-
itoring antiviral therapy with nucleoside analogs. The high level of sensitivity, specificity, accuracy, and rapidity provided by
the LightCycler instrument are favorable for the use of this system in the detection of HHV-5 DNA in clinical specimens.
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SHORT COMMUNICATION
INTRODUCTION
Human herpesvirus 5 (HHV-5, formerly CMV),
from the β-Herpesvirinae  subfamily, is widely spread
within the population [9]. Primary HHV-5 infection is
usually asymptomatic and leads to latent infection of
macrophages, the CD8+ subpopulation of lymphocytes
T, and probably also endocrine glands cells [12]. HHV-5
infections are thus a serious matter of concern in the
group of immunocompromised patients [9]. The most
frequent clinical syndromes noted include cytome-
galovirus pneumonia, myelosuppression syndrome [16],
exacerbation of graft-versus-host disease (GvHD) [9],
and increased risk of secondary bacterial and fungal
infections [6]. In most laboratories, two main methods
are used for the quantitative detection of HHV-5
viremia; the first is based on PCR/hybridization/colori-
metric detection of the product and the second is the
real-time PCR technique[15]. 
Transplantation of allogenic hempoietic stem cells is
a therapeutic option in many hematological malignan-
cies, bone marrow deficiencies, and inherited immunod-
eficiency syndromes [3, 13, 17]. Because of the insuffi-
cient number of classic, HLA-matched donors of
hempoietic stem cells, umbilical cord blood (UCB) has
became considered an alternate and widely accepted
source of hempoietic cells [2, 14, 17]. In adult graft
recipients, the main limitation of UCB usage is the
insufficient number of progenitor cells in the trans-
planted material [3, 13, 17]. A possible way to overcomethis problem consists of transplanting multiple units of
UCB from various unrelated donors (transplantation of
so-called mixed UCB) [1, 7, 17, 18]. UCB as the source
of hempoietic stem cells, despite its particular disadvan-
tages, has two considerable advantages: availability and
low risk of viral contamination (especially with
cytomegalovirus and Epstein-Barr virus) [17]. 
In this article, a case of infection-related complica-
tions (especially HHV-5 reactivation) in a patient with
chronic myeloid leukemia after transplantation of two
UCB units obtained from two unrelated donors is
described along with a comparison and evaluation of the
usefulness of two viral DNA detection methods (Fig. 1).
Case report
Chronic myeloid leukemia Ph+, bcr/abl+ in chronic
phase was diagnosed in a 21-year-old woman in
November 2001. The patient was initially treated with
hydroxycarbamide, and subsequently interferon (IFN)-α
(Intron A) therapy and then imatinib therapy (daily
dose: 400 mg) were introduced. Taking into considera-
tion the age of the patient, her resistance to both the
IFN-α and imatinib treatments used before, and the
lack of both related and unrelated matched donors, the
patient was qualified for transplantation of two units of
unrelated UCB [10, 14]. The calculated EBMT Risk
Score [8], used for estimating the transplant-related
mortality risk, was 3. Pre-transplantation examination of
the patient’s bone marrow cells using fluorescent in situ
hybridization revealed the presence of bcr/abl fusion in
100% of the analyzed cells. At this time the patient was
anti-HHV-5 IgG seropositive, but the result for anti-
HHV-5 IgM antibodies was negative. Both donors were
cytomegalovirus seronegative and compatible in four of
the six examined HLA antigens (Table 1). 
After myeloablative conditioning (BuCy200+ATG-
-Fresenius) on December 20, 2004 (3 years after diagno-
sis), 3.7×107/kg nuclear cells and 0.6×105/kg CD34+ cells
were transplanted in total. Oral acyclovir was used as
a routine viral prophylaxis, fluconazole for the prevention
of fungal infections, and cyclosporine Awas introduced on
day –1 as a prevention of acute GvHD. On day +9 after
transplantation, during the period of myelosuppression,
pyrexia in the patient was observed; empiric antibiotic
therapy with a broad-spectrum agent was applied.
Streptococcus mitis, sensitive to the antibacterial agents
used, was isolated from the one of the patient’sblood sam-
ples. On the next day (day +10) the patient revealed res-
piratory insufficiency with gradually growing intensity. In
chest X-ray massive alveolar infiltration was noted, main-
ly in both hilar regions. The decision to mechanically ven-
tilate was taken. The patient was treated empirically with
methylprednisolone, broad-spectrum antibiotics, antifun-
gal agents, acyclovir, granulocyte colony-stimulating fac-
tor, and intravenous immunoglobulin G (IVIG). After
this empirical treatment an improvement in respiratory
function was noted, and on day +19 after transplantation
the patient was extubated.
Diffuse changes of “milk-glass” appearance obser-
ved in both lungs in a control CT-scan of the chest were
explained as atypical pneumonia. The results of micro-
biological and viral tests obtained during this period
were negative. In routinely performed (twice weekly)
qualitative PCR tests screening for HHV-5 [4], no
cytomegalovirus DNA was detectable before day +42
after transplantation. The first blood sample with
a detectable amount of viral DNA occurred on day +43.
Then intravenous ganciclovir (5 mg/kg body weight
every 12 h) as a preemptive strategy was administered,
at an HHV-5 viremia level of 1300 copies/ml. At the
same time the patient presented with pyrexia and pneu-
monia of unclear etiology on x-ray and CT scans, so
IVIG (0.5 g/kg) was co-administered. Because the etiol-
ogy of pneumonia was unclear, the patient received
antibiotics (ceftriaxone and clarithromycin i.v.). This
treatment (ganciclovir and antibiotics) was continued
until day +75 after transplantation (until DNA HHV-5
results were negative in two subsequent tests).
Chimerism was regularly estimated with the
microsatellite method. On day +30, mixed chimerism
was detected: 40% DUCB 7378 (male baby) donor cells
and 60% recipient cells. In the cytogenetic examination
of bone marrow cells performed on +50 day after trans-
plantation, mixed chimerism was detected: improper
mosaic kariotype 46, XX, t(7;11)(q11.2;q23), t(9;22)
(q34;q11.2), and t(11;17)(p11.2;p13) [7]/46XY [130].
The XY line came from the hempoietic stem cells of the
donor. Finally, on day +90 the donor chimerism DUCB
7378 was detected in 100% of the analyzed cells.
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Fig. 1. Changes in the patient’s clinical status over time after UCB
transplantation.
Table 1. Characteristics of the selected umbilical cord blood
(UCB) units
UCB symbol HLA Blood group Sex
DUCB5926 A B DRB1 0 Rh-positive  female
24 38 *0901 (ccDEeKell–)
68 51 *1301
DUCB7378 A B DRB1 A Rh-positive male
24 38 *09XX (CcDeeKell–)
26 51 *13XX
PATIENT A B DRB1 A Rh-positive female
24 27  *0901 (ccDEeKell–)
25 38 *1301On day +78 after transplantation of UCB, the
patient was transferred to the primary care center and
still received periodical transfusions of platelet concen-
trates. Based on the information obtained from the
physicians in charge of the patient outside of the
Department of Hematology, Oncology, and Internal
Medicine, it was determined that the patient had anoth-
er three onsets of cytomegalovirus reactivation (in
March, April, and June of 2005). From June of 2005
another problem of concern was therapy-resistant
autoimmunohemolytic anemia with the presence of
mixed IgG, IgM and IgA antibodies. After using all
available methods of therapy (methylprednisolone,
plasmaphereses, cyclofosfamide, rituximab, cyclospo-
rine A, mofetil mycophenolate, IVIG), on October 12,
2005 (day +296), it was decided to perform a splenecto-
my, which had no effect. On the fourth day after the
splenectomy the patient died. Histopathological exami-
nation of the spleen confirmed multifocal agglomera-
tions of neoplastic cells (myelosis leukemica) and hem-
orrhagic fields.
MATERIALS AND METHODS
Whole citrated blood was used for virological inves-
tigations of HHV-5. Blood was taken at one-week inter-
vals, starting from the second day after transplantation.
Qualitative PCR for detecting HHV-5 was performed
with 10 µl of DNA extracted from the patient’s blood
using a DNA Mini Kit (Qiagen®) according to manufac-
turer’s instruction. Amplification was carried out in
a final volume of 50 µl [4]. DNA of HHV-5 strain Ad169
was used as a positive control and DNA isolated from
the uninfected normal cell line HFFF-2 as a negative
control.
Initially, the number of HHV-5 DNA copies in pos-
itive samples was estimated using an Eclipse® CMV
DNA Detection Kit (IQ Products®), a quantitative
method based on PCR/hybridization/colorimetric detec-
tion of the product, according to the manufac-
turer’s instructions. For the confirmation of quantitative
results of viremia detection, real-time PCR was used.
Detection was made in a LightCycler 2.0 instrument
(Roche Diagnostics®) using a CMV LC PCR quantita-
tive commercial kit (Artus®). Fluorochrome-labeled
probes, complementary to the sequence lying within the
amplified PCR product, were used in this test. The
range of the control DNA calibrators was between 500
and 500,000 copies/ml. In accordance with the manufac-
turer’s recommendations, every sample was examined
twice.
RESULTS AND DISCUSSION
Amplification of DNA isolated from blood using
HHV-5-specific PCR [4] resulted in specific products
detected in samples taken between days 43 and 65 after
UCB transplantation (Fig. 2). The quantitative results
obtained by the Eclipse® CMV Detection Kit indicated
an initial increase in viremia level and its subsequent
decrease, probably resulting from the introduction of
antiviral therapy (Fig. 3). Similar results were recorded
with the real-time PCR method, but in this case
increased detection sensitivity was observed, especially
in the final stage of infection, when low-copy viremia
was noted (Fig. 3).
In this study we compared two methods applied for
the quantitative detection of cytomegalovirus DNA: the
Eclipse® CMV DNA Detection Kit (PCR/hybridiza-
tion/colorimetry) and real-time PCR using the CMV LC
PCR quantitative commercial kit. The greatest differ-
ence in the results obtained with real-time PCR was at
the level of 5.8%, in the samples where maximum
viremia was observed. In the same samples, the results
of real-time PCR and the second method, based on
PCR/hybridization/colorimetry, expressed as the num-
ber of viral DNA copies per milliliter of blood, differed
by 16%. It seems that both methods are comparable in
terms of their sensitivity and ability to detect low-copy-
-number HHV-5 viremia. However, real-time PCR has
one major advantage: it is much less time and lab-work
consuming. With real-time PCR, sample preparation
and test performance takes approximately 2.5 h, while
the time required to complete an examination using the
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Fig. 2. PCR qualitative detection of HHV-5.
Product electrophoresis was performed on
1% agarose gel stained with ethidium bro-
mide.Eclipse® CMV DNA Detection Kit took two workdays.
The latter method is also more sensitive to laboratory
errors. The comparison of the two methods used in the
present study indicates that employing real-time PCR is
advisable in common post-transplantation diagnostics.
Its sensitivity level guarantees detection of virus reacti-
vation even when it is present in the blood at a low-copy
level [15]. In addition, the convenience of use and the
short time of test performance make this method suit-
able for both screening and monitoring cytomegalovirus
DNA level.
Immediate detection of virus DNA in the blood
allows early introduction of the proper antiviral therapy.
The efficacy of hemotherapy depends considerably on
the virus replication level in the blood cells [5] and usu-
ally decreases together with the time passed from the
beginning of infection. Ganciclovir therapy, which is
routinely used despite its myelotoxic activity, often does
not give the desired outcomes because of the growing
number of resistant strains of HHV-5 [11]. Still, ganci-
clovir remains the therapy-of-choice in the preemptive
strategy. Foscarnet is considered an equivalent drug in
the preemptive strategy for patients with HHV-5 reacti-
vation after hempoietic cell transplantation. This drug
elicits resistance in HHV-5 strains much more slowly
and is also much less myelotoxic than ganciclovir, but
because of its nephrotoxicity, foscarnet is also burdening
to the patient [11]. It is thus important to reduce drug
administration with decreasing number of detected viral
DNA copies. One point of view is that initial therapy
should be given to the patient for at least two weeks, and
only after this period can one start to consider the prob-
lem of viral resistance; an earlier change of the drug is
not advised [1]. On the other hand, taking into account
the probability of latent virus reactivation, antiviral drug
toxicity, therapy costs, and the risk of initial viral resis-
tance, it is highly recommended to use a detection
method characterized by the highest available sensitivi-
ty and specificity as well as the development of an effi-
cient and reproducible method able to detect mutations
responsible for HHV-5 resistance against the nucleoside
analogues used in therapy.
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